FDA Clearance of Investigational New Drug for Patients with Krabbe Disease

We’re pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing patients and families affected by Krabbe disease about FBX-101 and our RESKUE Phase 1/2 trial: https://ulf.org/2021/01/fda-clearance-of-investigational-new-drug-for-patients-with-krabbe-disease/

0/5 (0 Reviews)